LHRH-targeted Nanogels As a Delivery System for Cisplatin to Ovarian Cancer

Overview

Journal Mol Pharm

Publisher American Chemical Society

Specialty Pharmacology

Date 2013 Aug 21

PMID 23957812

Citations 16

Authors

Natalia V Nukolova

Hardeep S Oberoi

Yi Zhao

Vladimir P Chekhonin

Alexander V Kabanov

Tatiana K Bronich

Affiliations

Soon will be listed here.

Abstract

Targeted drug delivery using multifunctional polymeric nanocarriers is a modern approach for cancer therapy. Our purpose was to prepare targeted nanogels for selective delivery of chemotherapeutic agent cisplatin to luteinizing hormone-releasing hormone (LHRH) receptor overexpressing tumor in vivo. Building blocks of such delivery systems consisted of innovative soft block copolymer nanogels with ionic cores serving as a reservoir for cisplatin (loading 35%) and a synthetic analogue of LHRH conjugated to the nanogels via poly(ethylene glycol) spacer. Covalent attachment of (D-Lys6)-LHRH to nanogels was shown to be possible without loss in either the ligand binding affinity or the nanogel drug incorporation ability. LHRH-nanogel accumulation was specific to the LHRH-receptor positive A2780 ovarian cancer cells and not toward LHRH-receptor negative SKOV-3 cells. The LHRH-nanogel cisplatin formulation was more effective and less toxic than equimolar doses of free cisplatin or untargeted nanogels in the treatment of receptor-positive ovarian cancer xenografts in mice. Collectively, the study indicates that LHRH mediated nanogel-cisplatin delivery is a promising formulation strategy for therapy of tumors that express the LHRH receptor.

Citing Articles

Nanocarrier-mediated cancer therapy with cisplatin: .

Ranasinghe R, Mathai M, Alshawsh M, Zulli A Heliyon. 2025; 10(7):e28171.

PMID: 39839154 PMC: 11747978. DOI: 10.1016/j.heliyon.2024.e28171.

Lipid Horizons: Recent Advances and Future Prospects in LBDDS for Oral Administration of Antihypertensive Agents.

Preeti , Sambhakar S, Malik R, Bhatia S, Al Harrasi A, Saharan R Int J Hypertens. 2024; 2024:2430147.

PMID: 38410720 PMC: 10896658. DOI: 10.1155/2024/2430147.

Therapeutic dosing and targeting efficacy of Pt-Mal-LHRH towards triple negative breast cancer.

Ndinguri M, Middleton L, Unrine J, Lui S, Rollins J, Nienaber E PLoS One. 2023; 18(10):e0287151.

PMID: 37816015 PMC: 10564129. DOI: 10.1371/journal.pone.0287151.

Luteinizing Hormone Releasing Hormone-Targeted Cisplatin-Loaded Magnetite Nanoclusters for Simultaneous MR Imaging and Chemotherapy of Ovarian Cancer.

Vishwasrao H, Master A, Seo Y, Liu X, Pothayee N, Zhou Z Chem Mater. 2023; 28(9):3024-3040.

PMID: 37405207 PMC: 10317193. DOI: 10.1021/acs.chemmater.6b00197.

Conventional and new proposals of GnRH therapy for ovarian, breast, and prostatic cancers.

Garrido M, Hernandez A, Vega M, Araya E, Romero C Front Endocrinol (Lausanne). 2023; 14:1143261.

PMID: 37056674 PMC: 10086188. DOI: 10.3389/fendo.2023.1143261.

References

Kim J, Kabanov A, Bronich T . Polymer micelles with cross-linked polyanion core for delivery of a cationic drug doxorubicin. J Control Release. 2009; 138(3):197-204. PMC: 2728168. DOI: 10.1016/j.jconrel.2009.04.019. View

Nagy A, Schally A . Targeting of cytotoxic luteinizing hormone-releasing hormone analogs to breast, ovarian, endometrial, and prostate cancers. Biol Reprod. 2005; 73(5):851-9. DOI: 10.1095/biolreprod.105.043489. View

Vicent M, Duncan R . Polymer conjugates: nanosized medicines for treating cancer. Trends Biotechnol. 2005; 24(1):39-47. DOI: 10.1016/j.tibtech.2005.11.006. View

Low P, Henne W, Doorneweerd D . Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases. Acc Chem Res. 2007; 41(1):120-9. DOI: 10.1021/ar7000815. View

Nukolova N, Oberoi H, Cohen S, Kabanov A, Bronich T . Folate-decorated nanogels for targeted therapy of ovarian cancer. Biomaterials. 2011; 32(23):5417-26. PMC: 3255291. DOI: 10.1016/j.biomaterials.2011.04.006. View

Taratula O, Garbuzenko O, Kirkpatrick P, Pandya I, Savla R, Pozharov V . Surface-engineered targeted PPI dendrimer for efficient intracellular and intratumoral siRNA delivery. J Control Release. 2009; 140(3):284-93. PMC: 2787988. DOI: 10.1016/j.jconrel.2009.06.019. View

Bronich T, Keifer P, Shlyakhtenko L, Kabanov A . Polymer micelle with cross-linked ionic core. J Am Chem Soc. 2005; 127(23):8236-7. DOI: 10.1021/ja043042m. View

Segal E, Le Pecq J . Role of ligand exchange processes in the reaction kinetics of the antitumor drug cis-diamminedichloroplatinum(II) with its targets. Cancer Res. 1985; 45(2):492-8. View

Petros R, DeSimone J . Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov. 2010; 9(8):615-27. DOI: 10.1038/nrd2591. View

10.

Saad M, Garbuzenko O, Ber E, Chandna P, Khandare J, Pozharov V . Receptor targeted polymers, dendrimers, liposomes: which nanocarrier is the most efficient for tumor-specific treatment and imaging?. J Control Release. 2008; 130(2):107-14. PMC: 3590109. DOI: 10.1016/j.jconrel.2008.05.024. View

11.

NEWMAN M, Colbern G, Working P, Engbers C, Amantea M . Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice. Cancer Chemother Pharmacol. 1999; 43(1):1-7. DOI: 10.1007/s002800050855. View

12.

Duncan R . The dawning era of polymer therapeutics. Nat Rev Drug Discov. 2003; 2(5):347-60. DOI: 10.1038/nrd1088. View

13.

Taheri A, Dinarvand R, Ahadi F, Khorramizadeh M, Atyabi F . The in vivo antitumor activity of LHRH targeted methotrexate-human serum albumin nanoparticles in 4T1 tumor-bearing Balb/c mice. Int J Pharm. 2012; 431(1-2):183-9. DOI: 10.1016/j.ijpharm.2012.04.033. View

14.

Mohanty C, Das M, Kanwar J, Sahoo S . Receptor mediated tumor targeting: an emerging approach for cancer therapy. Curr Drug Deliv. 2010; 8(1):45-58. DOI: 10.2174/156720111793663606. View

15.

Todd R, Lovejoy K, Lippard S . Understanding the effect of carbonate ion on cisplatin binding to DNA. J Am Chem Soc. 2007; 129(20):6370-1. PMC: 2494524. DOI: 10.1021/ja071143p. View

16.

Oberoi H, Laquer F, Marky L, Kabanov A, Bronich T . Core cross-linked block ionomer micelles as pH-responsive carriers for cis-diamminedichloroplatinum(II). J Control Release. 2011; 153(1):64-72. PMC: 3134139. DOI: 10.1016/j.jconrel.2011.03.028. View

17.

Maeda H, Wu J, Sawa T, Matsumura Y, Hori K . Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000; 65(1-2):271-84. DOI: 10.1016/s0168-3659(99)00248-5. View

18.

Kim J, Nukolova N, Oberoi H, Kabanov A, Bronich T . Block Ionomer Complex Micelles with Cross-Linked Cores for Drug Delivery. Polym Sci Ser A Chem Phys. 2010; 51(6):708-718. PMC: 2994363. DOI: 10.1134/S0965545X09060169. View

19.

Sundaram S, Trivedi R, Durairaj C, Ramesh R, Ambati B, Kompella U . Targeted drug and gene delivery systems for lung cancer therapy. Clin Cancer Res. 2009; 15(23):7299-308. PMC: 2787834. DOI: 10.1158/1078-0432.CCR-09-1745. View

20.

Uchino H, Matsumura Y, Negishi T, Koizumi F, Hayashi T, Honda T . Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats. Br J Cancer. 2005; 93(6):678-87. PMC: 2361620. DOI: 10.1038/sj.bjc.6602772. View